Grace TherapeuticsNASDAQ: GRCE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Next earnings report:

13 November 2024

Last dividends:

N/A

Next dividends:

N/A
$31.84 M
-59%vs. 3y high
30%vs. sector
-vs. 3y high
-vs. sector
-21%vs. 3y high
29%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Mon, 04 Nov 2024 14:30:00 GMT
$3.14+$0.04(+1.29%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

Included in screeners

No data

What type of business is Grace Therapeutics?

Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.

What sector is Grace Therapeutics in?

Grace Therapeutics is in the Healthcare sector

What industry is Grace Therapeutics in?

Grace Therapeutics is in the Biotechnology industry

What country is Grace Therapeutics from?

Grace Therapeutics is headquartered in United States

What is Grace Therapeutics website?

https://www.acastipharma.com

Is Grace Therapeutics in the S&P 500?

No, Grace Therapeutics is not included in the S&P 500 index

Is Grace Therapeutics in the NASDAQ 100?

No, Grace Therapeutics is not included in the NASDAQ 100 index

Is Grace Therapeutics in the Dow Jones?

No, Grace Therapeutics is not included in the Dow Jones index

When was Grace Therapeutics the previous earnings report?

No data

When does Grace Therapeutics earnings report?

The next expected earnings date for Grace Therapeutics is 13 November 2024